Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 10,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 10,000 shares of Akero Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $28.03, for a total transaction of $280,300.00. Following the completion of the transaction, the chief operating officer now owns 218,083 shares in the company, valued at approximately $6,112,866.49. This trade represents a 4.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jonathan Young also recently made the following trade(s):

• On Tuesday, December 10th, Jonathan Young sold 2,503 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total transaction of $77,067.37.
• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.13, for a total transaction of $321,300.00.
• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.57, for a total transaction of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.15, for a total value of $1,206,000.00.

Akero Therapeutics Stock Performance

NASDAQ AKRO opened at $26.16 on Thursday. The business has a 50 day moving average price of $30.30 and a 200 day moving average price of $27.96. The company has a market capitalization of $1.83 billion, a P/E ratio of -6.98 and a beta of -0.19. Akero Therapeutics, Inc. has a 1-year low of $15.32 and a 1-year high of $37.00. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). Sell-side analysts expect that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the company. Citigroup initiated coverage on Akero Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $65.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a report on Monday, November 18th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Akero Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.83.

Hedge Funds Weigh In On Akero Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its stake in shares of Akero Therapeutics by 54.4% during the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after purchasing an additional 2,782,029 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Akero Therapeutics during the 3rd quarter valued at $37,392,000. RTW Investments LP increased its position in Akero Therapeutics by 9.0% during the third quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock worth $169,829,000 after buying an additional 487,450 shares in the last quarter. Long Focus Capital Management LLC raised its holdings in shares of Akero Therapeutics by 119.0% in the second quarter. Long Focus Capital Management LLC now owns 719,604 shares of the company’s stock worth $16,882,000 after acquiring an additional 391,000 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of Akero Therapeutics by 2.9% in the third quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock valued at $203,053,000 after acquiring an additional 201,225 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.